(CABA) – FDA
-
Cabaletta Bio (CABA) Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
-
Cabaletta Bio (CABA) Granted FDA Orphan Drug Designation to CABA-201
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to CABA Stock Lookup